New hope for kids with relapsed leukemia: early trial combines three drugs
NCT ID NCT03740334
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of three drugs—ribociclib, everolimus, and dexamethasone—in children and young adults (ages 1 to 30) whose acute lymphoblastic leukemia has come back or not responded to standard treatment. The main goal is to find the safest dose and understand how the drugs move through the body. Up to 45 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ribociclib, everolimus, and dexamethasone
What this could lead to
If it works, this could point toward a new treatment option for children and young adults with relapsed acute lymphoblastic leukemia.
What could go wrong
This is a very early phase 1 trial with only 45 participants, focused on finding a safe dose. It is too small to prove effectiveness, and the drugs may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10174, United States
-
Nemours/Alfred I. duPont Hospital for Children
Wilmington, Delaware, 19803, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States